EGLN2 and cancer: Moreover, as the HIF-PHIs now in use indiscriminately inhibit PHD1–3 and can increase the levels of HIF-α isoforms, which potentially offer advantages in the hypoxemic adaptation of cancer, we argue for caution in this area.